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Abstract  28 
Background: Reports of altered endogenous neurogenesis in people with Alzheimer‟s disease (AD) 29 
and transgenic AD models have suggested that endogenous neurogenesis may be an important 30 
treatment target, but there is considerable discrepancy between studies. We examined endogenous 31 
neurogenesis and glia changes across the range of pathological severity of AD in people with/without 32 
dementia to address this key question.  33 
Methods: Endogenous neurogenesis and glia in the subventricular zone and dentate gyrus 34 
neurogenic niches were evaluated using single and double immunohistochemistry and a validated 35 
antibody selection for stage-and-type-specific markers in autopsy tissue from a representative cohort 36 
of 28 participants in the MRC Cognitive Function and Ageing study (MRC CFAS). Immunopositive 37 
cells were measured blinded to diagnosis, using brightfield and fluorescent microscopy.  38 
Results: The number of newly-generated neurons significantly declined only in the dentate gyrus of 39 
patients with severe tau pathology. No other changes in other neurogenic markers were observed in 40 
either of the neurogenic niches. Interestingly, alterations in astrocytes and microglia were also 41 
observed in the dentate gyrus across the different stages of tau pathology. No change in any of the 42 
markers was observed in individuals who died with dementia compared to those who did not.  43 
Conclusions: Alterations in endogenous neurogenesis appear to be confined to a reduction in the 44 
generation of new neurons in the dentate gyrus of AD patients with severe neurofibrillary tangle 45 
pathology and were accompanied by changes in the glia load. These data suggest that intervention 46 
enhancing endogenous neurogenesis may be a potential therapeutic target in AD.   47 
48 
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Introduction   49 
Dementia currently affects more than 34 million people worldwide, with estimations that more than 50 
110 million people will be affected by dementia in 2050 (1). Alzheimer‟s disease (AD), the most 51 
common form of dementia, causes enormous personal, social and financial burdens on the patients, 52 
their caregivers and society. Current pharmacological treatments offer symptomatic benefits, thus 53 
effective disease-modifying therapies are urgently needed. As AD is a neurodegenerative disease, 54 
cell replacement strategies are a potential target for therapeutic intervention; such as promoting 55 
endogenous neurogenesis.  56 
Endogenous neurogenesis is evident in two areas of the brain: the hippocampal dentate gyrus (DG) 57 
and the wall of the lateral ventricles (subventricular zone–SVZ) (2-5). In mammals, neural 58 
progenitors at the base of the DG granular layer (subgranular layer, SGL) give rise to neurons that 59 
can be functionally integrated in the granular cell layer, whereas the SVZ neural progenitors follow a 60 
distinct pathway, the Rostral Migratory Stream (RMS), to the olfactory bulb (OB) where they create 61 
interneurons. In the healthy adult brain, SVZ neurogenesis maintains cellular turnover in the OB, 62 
contributing to olfactory adaptation and learning (6-8), whereas in DG endogenous neurogenesis is 63 
crucial for the hippocampal-dependent spatial learning and memory throughout life (8-11). 64 
Groundbreaking work over the last two decades has demonstrated the presence of the same 65 
neurogenic niches in the adult human brain, including the temporal horn of the lateral ventricles, 66 
located adjacent to the hippocampal formation (12-15). Consequently, there has been evolving 67 
interest in the therapeutic potential of strategies that aim to enhance endogenous neurogenesis. Many 68 
available compounds, of which some are already in clinical use, such as retinoid agonists, 69 
cannabinoids, Selective Serotonin Reuptake Inhibitors (SSRIs), cholinesterase inhibitors and certain 70 
hormones have a substantial positive impact on neurogenesis in animals, by either stimulating 71 
proliferation of endogenous neural stem cells and/or increasing their differentiation into neurons (for 72 
reviews see 16 and 17). 73 
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However, the potential clinical relevance for AD patients is less clear, with contradictory results 74 
from the small number of human autopsy studies that have been undertaken. Ziabreva et al. (2006) 75 
and Perry et al. (2012) identified an increase at the proliferation stages of neurogenesis in the anterior 76 
SVZ (18) and the temporal horn SVZ and DG (19) respectively, but a reduction in the early stage 77 
neural progenitors in the SVZ of AD patients compared to age-matched controls (18). In a previous 78 
study from our group foucssing on a different cohort of AD patients, including people with 79 
concurrent cerebrovascular disease, no statistically significant difference was observed in early 80 
neuronal marker immunoreactivity between AD and controls (19).  In contrast, in another study 81 
increased numbers of neural progenitors were detected in the DG of AD patients, which resulted in 82 
an unsuccessful maturation to newly-generated neurons (20). In a report focusing on younger 83 
patients with AD, increased glial proliferation was reported in the SGL, but no alteration in 84 
neurogenesis was identified (21). Other studies suggested that both concurrent cerebrovascular 85 
pathology (22-26) and the severity of cortical cholinergic system deficits (18, 19, 27) are likely to 86 
represent key mediating factors in either increasing or decreasing endogenous neurogenesis, 87 
respectively. Hence, the influence of age-associated neuropathological changes on neurogenesis is 88 
not fully elucidated, in particular with respect to the early stages of the AD process.  89 
Similar to the often contradictory data from studies on human tissue, studies investigating 90 
neurogenesis in transgenic animal models carrying the human mutations for APP and/or PS1 or PS2 91 
and/or tau proteins reported increased, decreased or unchanged progenitor activity (28-32).  92 
To further elucidate the role of neurogenesis in AD, we examined post mortem brain tissue from a 93 
subset of participants of the Medical Research Council Cognitive Function and Ageing Study (MRC 94 
CFAS), including individuals who died with and without dementia, and who showed all 95 
neuropathological stages of AD-associated tau pathology (i.e., Braak stages 0 to VI), without any 96 
other neuropathology such as cerebrovascular disease. For the first time, the levels of astrocytic and 97 
microglia cell numbers were also identified in the different Braak stages. Our study primarily aimed 98 
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to identify alterations in the various phases of endogenous neurogenesis in relation to dementia and 99 
AD-associated pathology. 100 
 101 
 Methods and Materials 102 
Tissue was obtained from brains donated to the UK MRC CFAS. Details of the study have been 103 
described elsewhere (33, 34) and can also be found at the website (www.cfas.ac.uk). In brief, MRC 104 
CFAS included an initial cohort of 13,004 individuals, representative of the population aged 65 and 105 
over recruited from general practice lists in five areas of England and Wales. The cohort for the 106 
current study consists of 28 brain samples selected from those participants of the MRC CFAS who 107 
agreed to donate their brain on death and among whom a successful autopsy was performed. At the 108 
time of sampling, 456 brain donations had been made to the study, 114 of which were available and 109 
had sufficient tissue for the current analysis (those from the Cambridgeshire and Newcastle centres). 110 
Those who received a neuropathological diagnosis of „normal brain‟, „possible AD‟, „probable AD‟ 111 
or „definite AD‟ were considered for selection into the study. Those with any diagnosis of Lewy 112 
body disease, cerebrovascular disease or other neuropathology were excluded. Neurofibrillary tangle 113 
(NFT) pathology was assessed using Braak staging (35-37) after histochemistry, by experienced 114 
neuropathologists working in the MRC CFAS study, blinded to clinical findings (supplementary 115 
figure S1). Neurofibrillary Braak stages are stated based on the topographical distribution of  116 
neurofibrillary tangles and neuropil threads which are neuropathological hallmark lesions of AD; at 117 
Braak stages I and II, NFTs are confined mainly to the transentorhinal region of the brain; at stages 118 
III and IV they are also found in limbic regions such as the hippocampus, and at the severe stages V 119 
and VI they are extensively located in other brain areas, including the neocortex (35, 36).  The 120 
neuropathological diagnosis of AD was done according to internationally accepted criteria that 121 
include the assessment of amyloid-β pathology, which progresses spatially and temporally 122 
differently than the tau pathology. Of note, similar to many other studies, we used Braak stages to 123 
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indicate the overall severity of AD pathology, but not to directly compare the severity of tau 124 
pathology with neurogenesis; in this study neither tau nor amyloid-β pathology was directly 125 
compared with neurogenesis in the same topographic locations.  126 
Diagnosis of dementia 127 
Dementia status at death was determined based on interviews during the last years of life, including 128 
the full GMS-AGECAT diagnostic algorithm that was equivalent to that in the Diagnostic and 129 
Statistical Manual of Mental Disorders, third edition, revised (DSM-III-R), interviews with 130 
informants after the respondent's death when this was possible and death certification (37). Of the 28 131 
individuals included in the present study, 13 received a study diagnosis of dementia at death. 132 
Demographic data are shown in table 1.  133 
Immunohistochemistry 134 
8m thick, paraffin- embedded sections were obtained at the level of basal ganglia, including the 135 
anterior SVZ, and also at the level of hippocampus, including the temporal horn of the SVZ. Slides 136 
were processed for immunohistochemistry and double immunofluorescence (described in 137 
supplementary Methods and Materials), according to previously published procedures (22, 23, 26, 138 
27). 139 
Cell counts 140 
Cell counting was performed twice, blind to the clinical and neuropathological diagnosis, using a 141 
Nikon Eclipse E800 microscope and the NIS elements software for bright field microscopy (version. 142 
2.3, both from Nikon Europe, Nederlands) and a Carl Zeiss Apotome Axioplan 2 microscope and the 143 
AxioVision software for the immunofluorescence (version 4.7.2, all from Carl Zeiss, UK). The 144 
length of the hippocampus and that of three areas of the SVZ and the neighbouring ependymal cell 145 
layer in either the anterior ventricle horn or the temporal ventricle horn were measured on each slide 146 
section under a very low magnification and using the relevant microscope software tools. Results 147 
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were expressed as the number of immunopositive cells for each antibody/mm of length for all the 148 
markers, in order to adjust for variances due to different lengths of the areas measured.  149 
Statistical analysis 150 
For all markers except doublecortin, negative binomial regression analysis was used to model the 151 
difference in the number of immunopositive cells per mm length across groups defined by Braak 152 
stage.  Regression models were adjusted for age at death and for gender. Differences in cell counts 153 
per mm between those with and without dementia at autopsy were assessed by negative binomial 154 
regression adjusting for age at autopsy, gender and Braak stage. Negative binomial regression is a 155 
count based regression model, and allows a number of events (immunopositive cells) to be modelled 156 
in terms of covariates of interest (Braak stage and dementia diagnosis), as well as potentially 157 
confounding covariates (age and sex), while also taking into account differences in an „exposure‟ 158 
variable (length of tissue sample being examined). Negative binomial regression is a generalisation 159 
of Poisson regression in that it allows for heterogeneity in the number of cells per mm across 160 
individuals within a group. Poisson regression assumes an even distribution of immunopositive cells 161 
across samples within groups and would lead to Type 1 errors since this assumption is highly 162 
unlikely to be met. Negative binomial regression results in an estimate of „rate‟ (cells per mm) in 163 
each group standardised to remove the effect of any differences in age and sex across groups and an 164 
estimate of difference in terms of an „incident rate ratio‟ corresponding to the ratio of the rates across 165 
groups, assuming all other covariates held constant. It should be noted that the rate estimate is very 166 
similar to the raw count of cells/mm in each case, suggesting that the effect of any difference in age 167 
and sex across groups in this analysis is minimal. 168 
As a secondary albeit more conventional analysis, we conducted an analysis of variance (ANOVA) 169 
across groups treating total cells per mm as a continuous outcome. This led to substantively similar 170 
results, however it is likely that the outcome measure of cells per mm violates the assumptions of an 171 
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ANOVA (normally distribution with equal variances across groups) and so we prefer the negative 172 
binomial regression as the primary analysis. 173 
The numbers of cells positive for doublecortin were too small for meaningful multivariate analysis or 174 
analysis using a count-based regression model, and so for each brain area the proportion of cases 175 
with any doublecortin positive cells was compared across groups using Fisher‟s exact tests.  176 
An initial p value of p<0.05 was set for statistical significance, however owing to the large number 177 
of hypotheses considered, we subsequently corrected for multiple testing using the method of 178 
Benjamini and Hochberg (38) by setting a false discovery rate of q=0.05, leading to a revised critical 179 
value of p<0.0016 for each individual hypothesis. Finally, Spearman‟s correlation coefficients were 180 
estimated to identify any association between the detected changes. For the data analysis, IBM SPSS 181 
(version 19) and STATA (version 12.1) statistical software were used.  182 
 183 
Results  184 
Demographic data for the cohort are presented in Table 1. Across the entire study cohort, the mean 185 
age at death was 84.8 years (+/- 8.6, range 71-103) and 50% of the participants were female (for 186 
details see table 1). Statistical analysis showed that the post mortem delay was not related either to 187 
Braak Stage and dementia diagnosis (p>0.05 for both) or to the cell counts of any of the markers 188 
examined (data not shown).  189 
The pattern of immmunoreactivity of the neural stem/progenitor cells and their progeny were 190 
consistent with our previous descriptions (22, 23). Nestin and doublecortin immunoreactivity was 191 
observed in cellular somata and processes, although in the case of doublecortin, immunoreactivity in 192 
the processes was rarely observed, possibly due to the post mortem delay, as described previously 193 
(21). As doublecortin is also expressed in astrocytes (39), any doublecortin-positive cells with 194 
astrocytic appearance (multiple processes) were excluded from counting. PCNA and HuC/D 195 
immunoreactivity were detected in the cell nucleus. Figure 1 (A and B) shows the different cell 196 
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types, as detected by DAB immunohistochemistry and double immunofluorescence in the 197 
hippocampal DG and the subventricular zone.  198 
 199 
Dentate gyrus 200 
The estimated number of immunopositive cells per mm length in the DG and the estimated 201 
frequency of cells across Braak stages, standardised to the average age at the time of autopsy and for 202 
gender is shown in figure 2 (A and B) for both neurogenic markers and glia. There was a lower 203 
number of HuC/D-positive post mitotic early neurons in the DG in individuals with Braak staging V-204 
VI (severe neuropathology) compared to those with Braak staging 0-II (p=0.032, Figures 1B and 205 
2A). 206 
A significantly higher number of microglia cells, as identified by Iba1 immunohistochemistry, were 207 
detected in individuals with Braak stage III-IV compared to the other two groups (p=0.033, Figures 208 
2B and 3). However, the differences in early neurons and microglia cells detected were not 209 
statistically significant after adjusting for multiple testing. 210 
There was a significantly lower number of GFAP-positive cells (identifying both neural stem cells 211 
and astrocytes) among those with Braak stage III-IV (IRR=0.6; 95% CI=0.4-0.9) compared to those 212 
with Braak stage 0-II, but a higher number among those in those in Braak stage V-VI (IRR=1.9; 95% 213 
CI=1.3-2.8), and this difference across Braak groups remained statistically significant after 214 
correction for multiple testing (p<0.0001, Figures 2B and 3). 215 
Table 2 shows the difference in cell numbers per mm between those with and without dementia, and 216 
the rate ratio standardised for age, gender and Braak stage. There is some evidence of an increase in 217 
HuC/D-positive cell numbers in those with dementia (adjusted IRR=2.1; 95% CI=1.0-4.3; p=0.05). 218 
As the number of doublecortin-positive cells was very low in the DG, a different statistical analysis 219 
was performed, as described in Methods and Materials section. Table 3 shows the proportion of 220 
cases with doublecortin-immunopositive cells in each brain area examined, with some evidence that 221 
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these are more commonly found in the DG of those with higher Braak stages (Fisher‟s exact test 222 
p=0.05). All of the samples with doublecortin immunopositive cells in the DG were from 223 
participants who died with dementia (table 3, Fisher‟s exact test p=0.04), however owing to small 224 
numbers of samples and the large number of hypotheses considered these findings should be treated 225 
with caution. 226 
In order to examine potential correlations between the neurogenic and glial markers we performed 227 
Spearman‟s correlation (rho) analysis. There was a significant positive association between newly-228 
generated neurons and the activated microglia (R=0.52, p=0.005), but negatively associated with the 229 
changes of astrocytic cell numbers (R=-.396, p=0.045) in the DG (Table 4). 230 
 231 
SVZ and ependymal cell layer (anterior and temporal horn) 232 
The neurogenic markers remained unchanged at the anterior (at the level of basal ganglia) and 233 
temporal (at the level of hippocampus) horns of the SVZ  and the ependymal cell layer adjacent to 234 
those when analysed by Braak stage and by the presence of dementia (supplemental table S1 and 235 
table 3). PCNA-HuC/D double and HuC/D single immunolabelled cells were not detected in these 236 
areas.  237 
The astrocytic and microglia markers also remained unchanged in the SVZ neurogenic niche and 238 
neighbouring ependymal cell layer in Braak stages 0 to VI (supplemental table S1). 239 
 240 
Discussion 241 
A detailed analysis of endogenous neurogenesis in both neurogenic niches at various stages of tau 242 
pathology in 28 people with and without AD was undertaken from a representative community 243 
cohort of patients followed to autopsy (MRC CFA Study). This is a population-based representative 244 
pilot study of endogenous neurogenesis in AD using human autopsy tissue, and focuses on the full 245 
range of pathological disease severity, the cognitive status and both neurogenic niches from each 246 
individual, compared to our previous studies (18, 19). Furthermore, the study has the methodological 247 
11 Ekonomou 
 
advantage of excluding patients with concurrent cerebrovascular pathology, Lewy body disease and 248 
any other pathology that have been found to affect adult endogenous neurogenesis (22-27, 40), as 249 
opposed to previous studies of endogenous neurogenesis in AD (20, 21), including our previous 250 
studies focussing on different patient cohorts (18, 19) where the percentage area of immunoreactivity 251 
was measured rather than number of immunopositive cells.  252 
There were limited but statistically significant changes in one of the markers used in this study in 253 
individuals with dementia or at the different Braak stages. Specifically, we observed a significant 254 
reduction in newly generated neurons, as determined by single HuC/D immunohistochemistry, but 255 
not neural progenitors as determined by nestin, doublecortin and double PCNA-HuC/D 256 
immunolabelling in people with severe tau pathology (Braak stage V and VI), compared to those 257 
with no significant tau changes (Braak stage 0-II). Interestingly and consistent with other recent 258 
studies about the role of microglia in modulating endogenous neurogenesis, there was a significant 259 
relationship with activated microglia.  260 
There were no changes in neural stem cells or progenitors in the anterior and temporal horn of the 261 
SVZ, which is in contrast with the increased numbers of neural stem cells and progenitors observed 262 
in the SVZ of patients suffering from stroke, vascular dementia, dementia with Lewy bodies and 263 
small vessel disease, as our previous studies have shown (22, 23, 26, 27, 40). Markers of 264 
neurogenesis did not vary between those with and without dementia after adjusting for Braak stage, 265 
thus the reduced numbers of new neurons were specifically associated wih the severe Alzheimer 266 
pathology. 267 
Earlier studies examining endogenous neurogenesis in the course of AD have produced conflicting 268 
results, possibly because of the predominant focus on more severe AD, variable concurrent vascular 269 
changes and the limited focus on the later stages of neurogenesis, i.e. the newly-generated neurons. 270 
The only other study to examine early neurons, as well as progenitors, reported a significant 271 
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reduction on their maturation as marked by the the decreased levels of MAP2a and MAP2b isoforms 272 
in the DG of AD patients (20), consistent with our current findings.  273 
The present study exhibits some limitations, mainly due to methodology. As there are no reliable 274 
and/or applicable markers to “visualise” and follow the fate of  neural stem cells in the adult brain, it 275 
is impossible to draw any conclusions about adult endogenous neurogenesis during the lifespan of 276 
the participants in the study, so all our results represent adult neural stem cells and their progeny at a 277 
single  time point, that of autopsy. Optimistically, the development of new technologies will 278 
facilitate this and clarify more the role of adult neurogenesis and its incolvement in cognitive decline 279 
in ageing and AD. 280 
As exclusion criteria were applied to the cases in reference to the presence of other 281 
neurodegenerative diseases, our sample was modest (n=28), but it was a population-representative  it 282 
is pilot study of endogenous neurogenesis focussing upon “pure” AD in human autopsy tissue, 283 
including individuals with different stages of  AD pathology.  284 
The use of antibodies as markers of endogenous neurogenesis on human autopsy tissue represents a 285 
challenge, but we employed a validated battery of antibodies for the identification of progenitors and 286 
newly-developed neurons at the various stages of neurogenesis in human autopsy tissue. Long post-287 
mortem delay, quite common factor for obtaining human tissue, has been shown to alter but not 288 
eliminate the immunostaining pattern for doublecortin, with similar overall levels of staining but 289 
reduced staining within the soma. For example, Boekhoorn et al. (2006) have shown that post 290 
mortem delay reduced immunoreactivity within the dendrites of doublecortin-positive neuroblasts 291 
(21). A similar pattern was seen for doublecortin in our study, but importanly the changes in the 292 
overall pattern of staining by dementia stage were similar for other markers of neuroblasts/immature 293 
neurons (HuC/D with PCNA). As it has been suggested that DCX can also be expressed in astrocytes 294 
(39) and in dormant cells in non neurogenic areas (41, 42), the  use of HuC/D as an additional 295 
marker for neuronal progenitors/early neurons is important and limits the  possibility of over-296 
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interpreting results obtained from DCX immunohistochemistry. In addition, post-mortem delay was 297 
not significantly correlated with the overall level of staining. Many hypotheses were explored and 298 
when a correction was applied to ensure a false discovery rate of less than 0.05 only the changes 299 
detected in the numbers of GFAP-immunopositive cells in the DG remained still statistically 300 
significant across groups.  301 
As there is an age-related decline in neurogenesis observed also in humans (43), our estimates have 302 
also been adjusted for age, which further confirms the validity of our results. Physical activity and 303 
certain pharmacological treatments such as SSRIs (for a review see 16, 17 and references therein) 304 
can have an impact on neurogenesis in rodent models (44-51 and for a review 16, 17). These were 305 
not specifically examined in the current study, but it is unlikely that the magnitude of these effects 306 
would be sufficient to confound the analysis.   307 
The PCNA immunohistochemistry (Figure 1B) also revealed a number of cells that are not co-308 
expressing the neuronal fate marker HuC/D (green only cells in figure 1B). Although these cells 309 
were not counted for the study, we can speculate that they could represent astrocytic, microglial, or 310 
endothelial cell proliferating progenitors or cells re-entering the cell cycle according to Yang et al. 311 
(2003) (52), although that was not observed in the DG.  312 
Our results still showed some evidence that although the early stages of endogenous neurogenesis 313 
remained unchanged throughout the different Braak stages, severe AD pathology had a detrimental 314 
effect on the numbers of newly-generated neurons in the DG of the affected individuals. In contrast, 315 
endogenous neurogenesis at all stages and areas remained unchanged in individuals with dementia 316 
compared to people without, suggesting that severe AD pathology impaired only the production of 317 
new neurons.  318 
We used Braak staging, a neurofibrillary tangle-based staging system, to describe the overall severity 319 
of AD. Amyloid and tau pathology both increase with increasing disease severity, and many other 320 
concurrent pathways related to a broad range of changes including inflammation and mitochondrial 321 
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function are activated. The specific mechanisms associated with the reduced production of new 322 
neurones in people with severe AD are therefore difficult to unravel from the results of the current 323 
study.  Previous work has however suggested that tau transgenic mice (29, 53) do have reduced 324 
neurogenesis, supporting the potential role of tau pathology as a contributor to this effect.    325 
 There was a significant positive correlation between the cell numbers of activated microglia and 326 
those of the newly-generated neurons in the DG, suggesting that the reduction in activated microglia 327 
in people with Braak stage V- VI tangle pathology may be a key driver for the decline in the newly-328 
produced neurons in these individuals, along with the presence of tangles. Microglia have an 329 
important role in adult neurogenesis in the healthy brain, as it has been demonstrated to control the 330 
numbers of newly-produced neuron in the hippocampus through apoptosis (54) and can have both 331 
pro- and anti- neurogenic effects, finely “tuning” adult neurogenesis (for a review see 55).   332 
For the first time, changes in GFAP-positive astrocytes have been examined at the various Braak 333 
stages. Though we have no knowledge of the causal factors of these changes, one can hypothesize 334 
that as astrocytes have a significant role in the support and protection of neurons in the healthy brain, 335 
the decrease identified at Braak stage III-IV, below the levels seen in individuals with Braak stage 0-336 
II, could be another contributing factor to the disease progression and pathology. The two-fold 337 
increase above the levels observed in the healthy brain in astrocytes numbers in the Braak stage V-VI 338 
could have a detrimental effect on the diseased brain, as it has been described for certain 339 
neurodegenerative diseases, including dementia (for a review see 56). A separate study further 340 
investigating this hypothesis could clarify that observation and the underlying mechanism(s).  341 
Our study examined the fate of neuronal progenitors and their progeny at the DG and the anterior 342 
and temporal horn SVZ and adjacent ependymal layers in various stages of AD, without any effect 343 
from concurrent cerebrovascular or other neuropathology, and showed that specific and significant 344 
reductions in newly-generated neurons were detected only in the DG of those with severe AD 345 
pathology, and were associated to the microglial load of the area. Previous studies (57-59) 346 
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identifying that abnormal endogenous neurogenesis relates to age-related learning impairment have 347 
indicated that the manipulation of endogenous neurogenesis may be a potential treatment target in 348 
people with AD.  As a cross-sectional autopsy study, our results have to be interpreted cautiously, 349 
but our findings do support the concept for an enhancement of aspects of endogenous neurogenesis, 350 
as a possible treatment target in AD. 351 
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 Table 1: Demographic data for the cases used in the present study 392 
                                      Braak stage 
            0-II                           III-IV                         V-VI 
 
Age (years) ± SD 
Gender 
 
Dementia 
Gender 
 
PM delay in 
hours median 
(IQR) 
n=12 
80.3±8.4 
Female: 5; Male: 7 
 
n=3 
Female: 2; Male: 1 
 
17.5 (12-28) 
 
n=11 
88.9±8.2 
Female: 8; Male: 3 
 
n=5 
Female: 4; Male: 1 
 
25 (7-27) 
n=5 
86.8±5.3 
Female: 1; Male: 4 
 
n=5 
Female: 1; Male: 4 
 
17.5 (9.5-33) 
 393 
Data represent the mean or median in each group. SD: standard deviation, PM delay: Post-mortem 394 
delay, IQR: InterQuartile Range.395 
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Table 2: Cell numbers and area lengths (mm) for the neurogenic markers in the human dentate gyrus by study diagnosis of dementia at death.   
Antibody No dementia (n=15) Dementia (n=13) 
 
Cells/mm        Adjusted            IRR 
(raw data)       Cells/mm 
 
Cells/mm     Adjusted              IRR 
(raw data)     Cells/mm 
 
Nestin  0.094     0.13 (0.08) Ref. 0.10  0.09 (0.05) 0.7 (0.1-4.0) 
HuC/D-PCNA 0.88 1.0 (0.3) Ref. 0.61   0.6 (0.2) 0.6 (0.2-1.6) 
HuC/D 0.74 0.6 (0.1) Ref. 0.73 1.3 (0.4) * 2.1 (1.0-4.3) 
GFAP 4.79 5.2 (0.7) Ref. 2.46   4.9 (0.5) 0.9 (0.7-1.4) 
Iba1 7.82 7.3 (1.9) Ref. 5.57   7.0 (2.2) 1.0 (0.4-2.3) 
Rates and incident rate ratios for the difference in cell density in the dementia group compared to the no dementia group are estimated by negative 
binomial regression, adjusted for Braak stage. Cells per mm are standardised to the sample age and gender and numbers in parentheses represent 
standard error; IRR = Incidence rate ratio adjusted for age and gender, numbers in parentheses represent 95% confidence interval.*: p=0.045. 
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Table 3: Occurrence of Doublecortin immunoreactivity in the adult human brain neurogenic niches   
Antibody Braak 0-II 
(n=12) 
Braak III-IV 
(n=11) 
Braak V-VI 
(n=5) 
Fisher’s 
exact test 
p-value 
No dementia 
(n=15) 
Dementia 
(n=13) 
Fisher’s 
exact test 
p-value 
        
DG     0 (0) 2 (20) 2 (40) 0.05 0 (0) 4 (31) 0.04 
SVZ 1 (8.3) 2 (20)        0 (0) 0.57 1 (7) 2 (15) 0.58 
EP 1 (8.3) 1 (10)        0 (0)        1.00 1 (7)     1 (8) 1.00 
SVZ BG     4 (33)        1 (9)        0 (0) 0.22   2 (13) 3 (23) 0.64 
EP BG     7 (58) 6 (54)  1 (20) 0.47   9 (60) 5 (38) 0.45 
 
The numbers represent number of samples with doublecortin immunopositive cells in each brain area by Braak stage and dementia status where number 
in parentheses show the % of the same samples in each subgroup by Braak stage and dementia status. SVZ BG: Subventricular Zone at the level of basal 
ganglia (anterior horn). EP BG: Ependymal cell layer at the level of basal ganglia, adjacent to SVZ BG.  
 
 
 
Table 4: Correlation analysis among the observed changes in the dentate gyrus 
 
 GFAP DG HuC/D DG Iba1 DG 
Spearman's rho GFAP DG R 1.000 -.396* -.476* 
HuC/D DG R -.396* 1.000 .524** 
Iba1 DG R -.476* .524** 1.000 
 
Statistical analysis was performed using a two-tailed Spearman‟s rho correlation analysis. R: correlation coefficient. Statistical significance: 
*: p < 0.05 and **: p < 0.01. 
20 Ekonomou 
 
References 
1. Alzheimer‟s Disease International: World Alzheimer report 2009. 
http://www.alz.co.uk/research/world-report. 
2. Lois C, Garcia-Verdugo JM , Alvarez-Buylla A (1996): Chain migration of neuronal 
precursors. Science 271: 978-981. 
3. Doetsch F, Garcia-Verdugo JM , Alvarez-Buylla A (1997): Cellular composition and three-
dimensional organization of the subventricular germinal zone in the adult mammalian brain. J 
Neurosci 17: 5046-5061. 
4. Palmer TD, Takahashi J , Gage FH (1997): The adult rat hippocampus contains primordial 
neural stem cells. Mol Cell Neurosci 8: 389-404. 
5. Ma DK, Bonaguidi MA, Ming GL , Song H (2009): Adult neural stem cells in the 
mammalian central nervous system. Cell Res 19: 672-682. 
6. Rochefort C, Gheusi G, Vincent JD , Lledo PM (2002): Enriched odor exposure increases the 
number of newborn neurons in the adult olfactory bulb and improves odor memory. J 
Neurosci 22: 2679-2689. 
7. Magavi SS, Mitchell BD, Szentirmai O, Carter BS , Macklis JD (2005): Adult-born and 
preexisting olfactory granule neurons undergo distinct experience-dependent modifications of 
their olfactory responses in vivo. J Neurosci 25: 10729-10739. 
8. Imayoshi I, Sakamoto M, Ohtsuka T, Takao K, Miyakawa T, Yamaguchi M, et al. (2008): 
Roles of continuous neurogenesis in the structural and functional integrity of the adult 
forebrain. Nat Neurosci 11: 1153-1161. 
9. Ge S, Yang CH, Hsu KS, Ming GL , Song H (2007): A critical period for enhanced synaptic 
plasticity in newly generated neurons of the adult brain. Neuron 54: 559-566. 
21 Ekonomou 
 
10. Kee N, Teixeira CM, Wang AH , Frankland PW (2007): Preferential incorporation of adult-
generated granule cells into spatial memory networks in the dentate gyrus. Nat Neurosci. 10: 
355-362.  
11. Tashiro A, Makino H , Gage FH (2007): Experience-specific functional modification of the 
dentate gyrus through adult neurogenesis: a critical period during an immature stage. J 
Neurosci. 27: 3252-3259.  
12. Eriksson PS, Perfilieva E, Bjork-Eriksson T, Alborn AM, Nordborg C, Peterson DA et al. 
(1998): Neurogenesis in the adult human hippocampus. Nat Med 4: 1313-1317. 
13. Sanai N, Tramontin AD, Quinones-Hinojosa A, Barbaro NM, Gupta N, Kunwar S, et al. 
(2004): Unique astrocyte ribbon in adult human brain contains neural stem cells but lacks 
chain migration. Nature 427: 740-744. 
14. Quinones-Hinojosa A, Sanai N, Soriano-Navarro M, Gonzalez-Perez O, Mirzadeh Z, Gil-
Perotin S, et al. (2006): Cellular composition and cytoarchitecture of the adult human 
subventricular zone: a niche of neural stem cells. J Comp Neurol 494: 415-434. 
15. Curtis MA, Kam M, Nannmark U, Anderson MF, Axell MZ, Wikkelso C, et al.  (2007): 
Human neuroblasts migrate to the olfactory bulb via a lateral ventricular extension. Science 
315: 1243-1249.  
16. Abrous DN, Koehl M , Le Moal M (2005): Adult neurogenesis: from precursors to network 
and physiology. Physiol Rev 85: 523-569. 
17. Vaidya VA, Vadodaria KC, Jha S (2007): Neurotransmitter regulation of adult neurogenesis: 
putative therapeutic targets. CNS Neurol Disord Drug Targets 6(5): 358-74.  
18. Ziabreva I, Perry E, Perry R, Minger SL, Ekonomou A, Przyborski S , Ballard C (2006): 
Altered neurogenesis in Alzheimer's disease. J Psychosom Res 61: 311-316. 
22 Ekonomou 
 
19. Perry EK, Johnson M, Ekonomou A, Perry RH, Ballard C, Attems J (2012): Neurogenic 
abnormalities in Alzheimer's disease differ between stages of neurogenesis and are partly 
related to cholinergic pathology Neurobiol Dis 47(2): 155-162.  
20. Li B, Yamamori H, Tatebayashi Y, Shafit-Zagardo B, Tanimukai H, Chen S, et al. (2008): 
Failure of neuronal maturation in Alzheimer disease dentate gyrus. J Neuropathol Exp Neurol 
67: 78-84. 
21. Boekhoorn K, Joels M , Lucassen PJ (2006): Increased proliferation reflects glial and 
vascular-associated changes, but not neurogenesis in the presenile Alzheimer hippocampus. 
Neurobiol Dis 24: 1-14. 
22. Ekonomou A, Ballard CG, Pathmanaban ON, Perry RH, Perry EK, Kalaria RN , Minger SL 
(2011): Increased neural progenitors in vascular dementia. Neurobiol Aging 32: 2152-2161. 
23. Ekonomou A, Johnson M, Perry RH, Perry EK, Kalaria RN, Minger SL, Ballard CG (2012): 
Increased neural progenitors in individuals with cerebral small vessel disease. Neuropathol 
Appl Neurobiol 38(4): 344-353. 
24. Jin K, Wang X, Xie L, Mao XO, Zhu W, Wang Y, et al.  (2006): Evidence for stroke-induced 
neurogenesis in the human brain. Proc Natl Acad Sci USA 103: 13198-13202.  
25. Macas J, Nern C, Plate KH , Momma S (2006): Increased generation of neuronal progenitors 
after ischemic injury in the aged adult human forebrain. J Neurosci 26: 13114-13119. 
26. Minger SL, Ekonomou A, Carta EM, Chinoy A, Perry RH , Ballard CG (2007): Endogenous 
neurogenesis in the human brain following cerebral infarction. Regen Med 2: 69-74. 
27. Johnson M, Ekonomou A, Hobbs C, Ballard CG, Perry RH , Perry EK (2011): Neurogenic 
marker abnormalities in the hippocampus in dementia with Lewy bodies. Hippocampus 21: 
1126-1136. 
23 Ekonomou 
 
28. Demars M, Hu YS, Gadadhar A , Lazarov O (2010): Impaired neurogenesis is an early event 
in the etiology of familial Alzheimer's disease in transgenic mice. J Neurosci Res 88: 2103-
2117. 
29. Hamilton LK, Aumont A, Julien C, Vadnais A, Calon F , Fernandes KJ (2010): Widespread 
deficits in adult neurogenesis precede plaque and tangle formation in the 3xTg mouse model 
of Alzheimer's disease. Eur J Neurosci 32: 905-920. 
30. Jin K, Galvan V, Xie L, Mao XO, Gorostiza OF, Bredesen DE , Greenberg DA (2004): 
Enhanced neurogenesis in Alzheimer's disease transgenic (PDGF-APPSw,Ind) mice. Proc 
Natl Acad Sci U S A 101: 13363-13367. 
31. Wen PH, Hof PR, Chen X, Gluck K, Austin G, Younkin SG, et al. (2004): The presenilin-1 
familial Alzheimer disease mutant P117L impairs neurogenesis in the hippocampus of adult 
mice. Exp Neurol 188: 224-237. 
32. Ermini FV, Grathwohl S, Radde R, Yamaguchi M, Staufenbiel M, Palmer TD, Jucker M 
(2008): Neurogenesis and alterations of neural stem cells in mouse models of cerebral 
amyloidosis. Am J Pathol 172: 1520-1528. 
33. Brayne C, McCracken C, Matthews FE (2006): Cohort profile: the Medical Research Council 
Cognitive Function and Ageing Study (CFAS). Int J Epidemiol  35: 1140-1145. 
34. Matthews FE, Brayne C, Lowe J, McKeith I, Wharton SB , Ince P (2009): Epidemiological 
pathology of dementia: attributable-risks at death in the Medical Research Council Cognitive 
Function and Ageing Study. PLoS Med 6: e1000180. 
35. Braak, H. and Braak, E. (1991): "Neuropathological stageing of Alzheimer-related changes". 
Acta Neuropathol 82 (4): 239–59.  
36. Braak H, Alafuzoff I, Arzberger T, Kretzschmanr H, Del Tredici K. (2006): Staging of 
Alzheimer disease-associated neurofibrillary pathology using paraffin sections and 
immunohistochemistry. Acta Neuropathol 112: 389–404. 
24 Ekonomou 
 
37. Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C; Medical Research 
Council Cognitive Function and Ageing Study (2009):  Age, neuropathology and dementia. N 
Engl J Med 360(22): 2302-2309. 
38. Benjamini Y and Hochberg Y (1995): Controlling the false discovery rate: A practical and 
powerful approach to multiple testing. Journal of the Royal Statistical Society, Series B, 57: 
289-300.  
39. Verwer RW, Sluiter AA, Balesar RA, Baayen JC, Noske DP, Dirven CM, et al. (2007): 
Mature astrocytes in the adult human neocortex express the early neuronal marker 
doublecortin. Brain. 130(Pt 12):3321-35.  
40. Ziabreva I, Ballard C, Johnson M, Larsen JP, McKeith I, Perry R, et al. (2007): Loss of 
Musashi1 in Lewy body dementia associated with cholinergic deficit. Neuropathol Appl 
Neurobiol 33(5): 586-590. 
41. Kremer T, Jagasia R, Herrmann A, Matile H, Borroni E, Francis F, et al., (2013): Analysis of 
adult neurogenesis: evidence for a prominent "non-neurogenic" DCX-protein pool in rodent 
brain. PLoS One, 8(5):e59269 
42. Martí-Mengual U, Varea E, Crespo C, Blasco-Ibáñez JM, Nacher J. (2013):  Cells expressing 
markers of immature neurons in the amygdala of adult humans. Eur J Neurosci. 37(1):10-22. 
43. Kempermann G, Gast D, Gage FH (2002): Neuroplasticity in old age: sustained fivefold 
induction of hippocampal neurogenesis by long-term environmental enrichment. Ann Neurol 
52(2): 135-43. 
44. van Praag H, Shubert T, Zhao C, Gage FH. (2005): Exercise enhances learning and 
hippocampal neurogenesis in aged mice. J Neurosci. 25(38): 8680-5. 
45. Leem YH, Lim HJ, Shim SB, Cho JY, Kim BS, Han PL (2009): Repression of tau 
hyperphosphorylation by chronic endurance exercise in aged transgenic mouse model of 
tauopathies. J Neurosci Res. 87(11): 2561-70. 
25 Ekonomou 
 
46. Marlatt MW and Lucassen PJ (2010): Neurogenesis and Alzheimer's disease: Biology and 
pathophysiology in mice and men. Curr Alzheimer Res 7(2): 113-25. 
47. Belarbi K, Burnouf S, Fernandez-Gomez FJ, Laurent C, Lestavel S, Figeac M, et al. (2011): 
Beneficial effects of exercise in a transgenic mouse model of Alzheimer's disease-like Tau 
pathology. Neurobiol Dis 43(2): 486-94.  
48. García-Mesa Y, López-Ramos JC, Giménez-Llort L, Revilla S, Guerra R, Gruart A, Laferla 
FM, et al. (2011): Physical exercise protects against Alzheimer's disease in 3xTg-AD mice. J 
Alzheimers Dis 24(3): 421-54. 
49. Marlatt MW, Potter MC, Lucassen PJ, van Praag H (2012): Running throughout middle-age 
improves memory function, hippocampal neurogenesis, and BDNF levels in female 
C57BL/6J mice. Dev Neurobiol. 72(6): 943-52.  
50. Marlatt MW, Potter MC, Bayer TA, van Praag H, Lucassen PJ. (2013):  Prolonged running, 
not fluoxetine treatment, increases neurogenesis, but does not alter neuropathology, in the 
3xTg mouse model of Alzheimer's disease. Curr Top Behav Neurosci.  15:313-40. 
51. Voss MW, Vivar C, Kramer AF, van Praag H. (2013): Bridging animal and human models of 
exercise-induced brain plasticity. Trends Cogn Sci., 17(10): 525-44.  
52. Yang Y, Mufson EJ, Herrup K (2003): Neuronal cell death is preceded by cell cycle events at 
all stages of Alzheimer's disease. J Neurosci. 23(7):2557-63. 
53. Hong XP, Peng CX, Wei W, Tian Q, Liu YH, Yao XQ, Zhang Y, Cao FY, Wang Q, Wang 
JZ (2010): Essential role of tau phosphorylation in adult hippocampal neurogenesis. 
Hippocampus 20(12):1339-49. 
54. Sierra A, Encinas JM, Deudero JJ, Chancey JH, Enikolopov G, Overstreet-Wadiche LS, et al. 
(2010): Microglia shape adult hippocampal neurogenesis through apoptosis-coupled 
phagocytosis. Cell Stem Cell. 7: 483-495. 
26 Ekonomou 
 
55. Ekdahl CT (2012): Microglial activation - tuning and pruning adult neurogenesis. Front 
Pharmacol 3: 411-419.  
56. Verkhratsky A, Olabarria M, Noristani HN, Yeh CY and Rodriguez JJ (2012): Astrocytes in 
Alzheimer's disease. Neurotherapeutics. 7(4): 399-412.  
57. Nyffeler M, Yee BK, Feldon J, Knuesel I. (2010): Abnormal differentiation of newborn 
granule cells in age-related working memory impairments.  Neurobiol Aging. 31(11): 1956-
74. 
58. Kim SE, Ko IG, Kim BK, Shin MS, Cho S, Kim CJ, et al. (2010): Treadmill exercise 
prevents aging-induced failure of memory through an increase in neurogenesis and 
suppression of apoptosis in rat hippocampus. Exp. Gerontol. 45(5): 357-65. 
59. Déry N, Pilgrim M, Gibala M, Gillen J, Wojtowicz JM, Macqueen G, Becker S. (2013): 
Adult hippocampal neurogenesis reduces memory interference in humans: opposing effects 
of aerobic exercise and depression. Front Neurosci. 7: 66.  
 
 
 
  
 
 
 
27 Ekonomou 
 
Figure legends 
 
Figure 1: Immunohistochemistry showing neurogenesis in the dentate gurus (DG) and the 
subventricular zone (SVZ) of the adult human brain. A: DAB immunohistochemistry for nestin (top 
left, arrows) and doublecortin (top right, arrow) depicting neural stem cell/progenitors and late neural 
progenitors, respectively in both neurogenic niches. Scale bar: 5um. B: Double immunofluorescence 
for HuC/D (red) and PCNA (green) in severe AD patients (Braak stage V-VI) and their age-matched 
controls (Braak stage 0-II). There are significantly less postmitotic immature neurons (arrows, 
HuC/D-immunopositive cells) in the DG of severe AD patients compared to their age-matched 
controls. Yellow arrowheads indicate proliferating neuronal progenitors/neuroblasts immunopositive 
for both PCNA (a proliferating marker) and the HuC/D antigen. Images i and ii show higher 
magnification of double labelled cells at Braak stage 0-II and V-VI, respectively.  Scale bar: 20um. 
C: Schematic representation of the markers used for the characterization of the different stages of 
neurogenesis in the present study. Gr: dentate gyrus granular layer, h: hilus, LV: lateral ventricle, 
Ep: Ependymal cell layer.  
 
Figure 2: Graph bars represent the adjusted mean number (±standard error) of immunopositive cells 
per mm of length of dentate gyrus for neurogenic (A) and glial (B) markers in AD patients at 
different Braak stages, adjusted for age and dementia status. *: p<0.05, **: p<0.001. 
 
Figure 3: Immunofluorescence for astrocytes (GFAP) and microglia (Iba1) in age-matched 
individuals at Braak stage 0-II and patients with moderate (Braak stage III-IV) and severe (Braak 
stage V-VI) tangle pathology. DG: dentate gyrus, h: hilus. Scale bar: 50m. 
Figure 1
Click here to download high resolution image
Figure 2
Click here to download high resolution image
Figure 3
Click here to download high resolution image
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Stage-Specific Changes in Neurogenic and Glial Markers in Alzheimer’s Disease 
Supplemental Information 
 
Supplementary Materials and Methods 
Immunohistochemistry 
After deparaffinization, rehydration and microwave pressure cooking antigen retrieval 
using 10 mM citrate buffer, pH 6, slides were processed for immunohistochemistry using DAB 
staining and double immunofluorescence. A validated battery of antibodies was used in order to 
identify the type of neural stem cells and progenitors as marked by nestin (1/200, Chemicon) (1) 
and doublecortin (1/200, Santa Cruz) (2) and immature neurons (HuC/D, 1/1000, Invitrogen) (3). 
In order to identify proliferating neuronal progenitors, double immunofluorescence was 
performed with HuC/D and an antibody against the proliferating cell nuclear antigen (1/1000, 
DAKO). Astrocytes were quantified using an antibody against glial fibrillary acidic protein 
(GFAP, 1/6000, Dako), which also marks adult neural stem cells. Although all GFAP-positive 
cells are astrocytes, only some of them are the adult neural stem cells. Microglial cells were 
labelled using the Iba1 antibody (1/1500, Wako, Japan). Counterstaining was performed using 
either haematoxylin (DAB staining) or Hoescht33258 (immunofluorescence). The endogenous 
lipofuscin autofluorescence was removed by a 10-minute incubation of the sections in a 0.5% 
Sudan Black B (SIGMA, UK) in 70% methanol solution, as previously described (4). Adjacent 
sections were incubated in the absence of the primary or secondary antibodies in order to 
determine non-specific antibody binding, and they were devoid of immunoreactivity (Figure S2B 
and S2C).  
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Figure S1. Examples for semi-quantitative scoring using immunohistochemistry for the AT8 antibody against hyperphosphorylated 
tau in hippocampal sections. (A) Low (arrow: neurofibrillary tangle; arrowhead: neuropil thread), (B) moderate and (C) high 
immunopositivity in the CA1 region of the human hippocampus. A denotes sparse pathology. Scale bar: 500 um, valid for all 
photomicrographs. DG, dentate gyrus.  
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Figure S2. (A) DAB immunohistochemistry for nestin and doublecortin (DCX), arrows, in the 
hippocampal dentate gyrus (DG) under X63 magnification. (B) Fluorescence immunohisto-
chemistry in the hippocampal DG after omission of the primary antibodies HuC/D and 
proliferating cell nuclear antibody (PCNA) and in the presence of fluorescence-conjugated 
donkey anti-mouse secondary antibodies Alexa®Fluor488 and AlexaFluor®568 antibodies under 
20X magnification. (C) DAB immunohistochemistry after omission of the primary antibodies 
nestin and doublecortin in the presence of HRP-conjugated anti-rabbit and anti-goat secondary 
antibodies. h, hilus; LV, lateral ventricle; Ep, ependymal cell layer; SVZ, subventricular zone.   
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Table S1. Neurogenic and glia markers at the anterior and temporal horn of the subventricular zone  
 
   
Stage 0-2 (n = 12)  Stage 3-4 (n = 11)  Stage 5-6 (n = 5) 
      
Cells/mm 
(raw data) 
Adjusted 
Cells/mm 
IRR  Cells/mm 
(raw data) 
Adjusted 
Cells/mm 
IRR  Cells/mm 
(raw data) 
Adjusted 
Cells/mm 
IRR 
Iba1 SVZ BG 8.28 7.5 (2.3) Ref.  8.82 9.6 (3.3) 1.3 (0.5-3.4)  3.64 5.0 (2.9) 0.7 (0.2-2.4) 
Iba1 EP BG 1.83 2.6 (1.3) Ref.  2.24 1.6 (0.7) 0.6 (0.1-2.4)  00.30 0.5 (0.6) 0.2 (0.02-2.3) 
GFAP SVZ BG 4.58 5.6 (2.9) Ref.  4.27 4.4 (2.1) 0.8 (0.2-2.7)  5.28 5.1 (3.6) 0.9 (0.2-5.0) 
GFAP EP BG 23.3 38.8 (20.1) Ref.  5.73 4.5 (2.6) 0.1 (0.02-0.8)  24.17 20.6 (16.5) 0.5 (0.05-5.3) 
Nestin SVZ BG 22.12 20.9 (7.0) Ref.  12.59 14.3 (5.9) 0.7 (0.2-2.1)  13.94 11.9 (5.7) 0.6 (0.2-1.7) 
Nestin EP BG 93.77 86.3 (26.3) Ref.  51.29 49.1 (15.8) 0.6 (0.2-1.5)  95.46 120.6 (54.4) 1.4 (0.5-3.8) 
Iba1 SVZ 
 
11.63 11.4 (2.2) Ref.  21.49 21.4 (3.9) 1.9 (1.1-3.3)  16.88 19.3 (5.3) 1.7 (0.9-0.6) 
Iba1 EP 
 
1.83 2.1 (0.6) Ref.  4.37 4.0 (0.9) 1.9 (0.9-4.1)  2.19 2.1 (0.9) 1.0 (0.4-2.7) 
GFAP SVZ 
 
15.12 14.8 (2.7) Ref.  19.10 19.7 (3.8) 1.3 (0.8-2.3)  17.5 17.3 (4.6) 1.2 (0.6-2.2) 
GFAP EP 
 
10 11.3 (3.4) Ref.  11.67 10.4 (3.1) 0.9 (0.3-2.2)  12.19 14.8 (7.0) 1.3 (0.5-3.8) 
Nestin SVZ 
 
15.93 16.9 (2.8) Ref.  20.67 22.1 (3.6) 1.3 (0.8-2.1)  17.81 14.2 (3.3) 0.8 (0.5-1.5) 
Nestin EP 
 
13.58 14.6 (4.5) Ref.  9.2 9.3 (3.1) 0.6 (0.3-1.6)  13.13 11.5 (5.0) 0.8 (0.3-2.2) 
Cells/mm and incident rate ratios (IRR) (compared to the group with Braak stage 0-2 as a reference) are estimated by negative binomial regression. 
Adjusted cells per mm are standardized to the sample age and gender and numbers in parentheses represent standard error. None of the 
differences across groups are statistically significant. GFAP, glial fibrillary acidic protein; SVZ BG, subventricular zone at the level of basal ganglia 
(anterior horn); EP BG, ependymal cell layer at the level of basal ganglia, adjacent to SVZ BG. 
Ekonomou et al. 
5 
Supplemental References 
1. Lendahl U, Zimmerman LB, McKay RD (1990): CNS stem cells express a new class of 
intermediate filament protein. Cell 60: 585-595. 
 
2. Brown JP, Couillard-Despres S, Cooper-Kuhn CM, Winkler J, Aigner L, Kuhn HG (2003): 
Transient expression of doublecortin during adult neurogenesis. J Comp Neurol 467: 1-10. 
 
3. Grandel H, Kaslin J, Ganz J, Wenzel I, Brand M (2006): Neural stem cells and neurogenesis 
in the adult zebrafish brain: origin, proliferation dynamics, migration and cell fate. Dev Biol 
295(1): 263-277. 
 
4. Schnell SA, Staines WA, Wessendorf MW (1999): Reduction of lipofuscin-like 
autofluorescence in fluorescently labeled tissue. J Histochem Cytochem 47: 719–730. 
 
